Clinical Trial Update: Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous Leukemia (AML) Patients [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of AZD1208 in Acute Myeloid Leukemia assessed safety, tolerability, pharmacokinetics and preliminary efficacy; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZD1208

Snippet

Sponsor: AstraZeneca | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: TERMINATED